8AACDB46-9BB3-42BA-871D-7A593F14430A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.1537450722733245
- age_years
- 61
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.444
- UV_RESPONSE_DN+0.409
- HEDGEHOG_SIGNALING+0.405
- OXIDATIVE_PHOSPHORYLATION+0.390
- ANDROGEN_RESPONSE+0.363
- MTORC1_SIGNALING+0.324
- ESTROGEN_RESPONSE_EARLY+0.311
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.311
- CHOLESTEROL_HOMEOSTASIS+0.289
- MITOTIC_SPINDLE+0.277
Top 10 suppressed
- ANGIOGENESIS-0.258
- WNT_BETA_CATENIN_SIGNALING-0.217
- E2F_TARGETS-0.192
- ALLOGRAFT_REJECTION-0.181
- COAGULATION-0.174
- IL6_JAK_STAT3_SIGNALING-0.173
- KRAS_SIGNALING_DN-0.115
- MYC_TARGETS_V1-0.093
- MYC_TARGETS_V2-0.085
- TNFA_SIGNALING_VIA_NFKB-0.081
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1D2F3ED9-6319-4661-9E41-9DC9C8342DE1 | — | — | 0.880 |
| 2 | AE988295-3046-4778-81C5-B787CAC92268 | — | — | 0.870 |
| 3 | 45B7816C-0A67-441C-8E80-656EAF2AD940 | — | — | 0.839 |
| 4 | 387C53ED-A9ED-481F-87D9-87090B690E0E | — | — | 0.837 |
| 5 | 1E2D87A6-48B8-47FA-A801-AFEA7E01E829 | — | — | 0.823 |
| 6 | 106E2A94-0366-4D5E-894F-41117C78E18C | — | — | 0.817 |
| 7 | CF764E50-B0F9-44DE-8B48-F8F5A8920240 | — | — | 0.814 |
| 8 | D65697C7-2DA7-43BA-ABE2-50CB08B0D126 | — | — | 0.803 |
| 9 | SRR934759 | — | — | 0.777 |
| 10 | 093A32DA-49D0-4F4C-9000-4F47B4700F4E | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.444 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.409 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.405 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.363 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.324 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.311 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.311 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.289 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.277 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.275 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.271 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.261 | Idelalisib | — uncovered |
| PEROXISOME | 0.258 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.243 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.239 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.217 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.212 | Inavolisib | — uncovered |
| APOPTOSIS | 0.203 | Idelalisib | — uncovered |